Rationale and design of the participant, investigator, observer, and data-analyst-blinded randomized AGENDA trial on associations between gene-polymorphisms, endophenotypes for depression and antidepressive intervention: the effect of escitalopram versus placebo on the combined dexamethasone-corticotrophine releasing hormone test and other potential endophenotypes in healthy first-degree relatives of persons with depression

Ulla Knorr; Maj Vinberg; Marianne Klose; Ulla Feldt-Rasmussen; Linda Hilsted; Anders Gade; Eva Haastrup; Olaf Paulson; Jørn Wetterslev; Christian Gluud; Ulrik Gether; Lars Kessing

doi:10.1186/1745-6215-10-66

Rationale and design of the participant, investigator, observer, and data-analyst-blinded randomized AGENDA trial on associations between gene-polymorphisms, endophenotypes for depression and antidepressive intervention: the effect of escitalopram versus placebo on the combined dexamethasone-corticotrophine releasing hormone test and other potential endophenotypes in healthy first-degree relatives of persons with depression

Ulla Knorr, Maj Vinberg, Marianne Klose, Ulla Feldt-Rasmussen, Linda Hilsted, Anders Gade, Eva Haastrup, Olaf Paulson, Jørn Wetterslev, Christian Gluud, Ulrik Gether, Lars Kessing

13 Citationer (Scopus)

Abstract

BACKGROUND: Endophenotypes are heritable markers, which are more prevalent in patients and their healthy relatives than in the general population. Recent studies point at disturbed regulation of the hypothalamic-pituitary-adrenocortical axis as a possible endophenotype for depression. We hypothesize that potential endophenotypes for depression may be affected by selective serotonin re-uptake inhibitor antidepressants in healthy first-degree relatives of depressed patients. The primary outcome measure is the change in plasma cortisol in the dexamethasone-corticotrophin releasing hormone test from baseline to the end of intervention. METHODS: The AGENDA trial is designed as a participant, investigator, observer, and data-analyst-blinded randomized trial. Participants are 80 healthy first-degree relatives of patients with depression. Participants are randomized to escitalopram 10 mg per day versus placebo for four weeks. Randomization is stratified by gender and age. The primary outcome measure is the change in plasma cortisol in the dexamethasone-corticotrophin releasing hormone test at entry before intervention to after four weeks of intervention. With the inclusion of 80 participants, a 60% power is obtained to detect a clinically relevant difference in the primary outcome between the intervention and the placebo group. Secondary outcome measures are changes from baseline to four weeks in scores of: 1) cognition and 2) neuroticism. Tertiary outcomes measures are changes from baseline to four weeks in scores of: 1) depression and anxiety symptoms; 2) subjective evaluations of depressive symptoms, perceived stress, quality of life, aggression, sleep, and pain; and 3) salivary cortisol at eight different timepoints during an ordinary day. Assessments are undertaken by assessors blinded to the randomization group.

Originalsprog	Engelsk
Tidsskrift	Trials
Vol/bind	10
Sider (fra-til)	66
ISSN	1745-6215
DOI	https://doi.org/10.1186/1745-6215-10-66
Status	Udgivet - 2009

Adgang til dokumentet

10.1186/1745-6215-10-66

Fingeraftryk

Dyk ned i forskningsemnerne om 'Rationale and design of the participant, investigator, observer, and data-analyst-blinded randomized AGENDA trial on associations between gene-polymorphisms, endophenotypes for depression and antidepressive intervention: the effect of escitalopram versus placebo on the combined dexamethasone-corticotrophine releasing hormone test and other potential endophenotypes in healthy first-degree relatives of persons with depression'. Sammen danner de et unikt fingeraftryk.

Citationsformater

Knorr, U., Vinberg, M., Klose, M., Feldt-Rasmussen, U., Hilsted, L., Gade, A., Haastrup, E., Paulson, O., Wetterslev, J., Gluud, C., Gether, U., & Kessing, L. (2009). Rationale and design of the participant, investigator, observer, and data-analyst-blinded randomized AGENDA trial on associations between gene-polymorphisms, endophenotypes for depression and antidepressive intervention: the effect of escitalopram versus placebo on the combined dexamethasone-corticotrophine releasing hormone test and other potential endophenotypes in healthy first-degree relatives of persons with depression. Trials, 10, 66. https://doi.org/10.1186/1745-6215-10-66

Rationale and design of the participant, investigator, observer, and data-analyst-blinded randomized AGENDA trial on associations between gene-polymorphisms, endophenotypes for depression and antidepressive intervention: the effect of escitalopram versus placebo on the combined dexamethasone-corticotrophine releasing hormone test and other potential endophenotypes in healthy first-degree relatives of persons with depression. / Knorr, Ulla ; Vinberg, Maj; Klose, Marianne et al.
I: Trials, Bind 10, 2009, s. 66.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Knorr, U , Vinberg, M, Klose, M, Feldt-Rasmussen, U , Hilsted, L, Gade, A, Haastrup, E, Paulson, O, Wetterslev, J, Gluud, C, Gether, U & Kessing, L 2009, 'Rationale and design of the participant, investigator, observer, and data-analyst-blinded randomized AGENDA trial on associations between gene-polymorphisms, endophenotypes for depression and antidepressive intervention: the effect of escitalopram versus placebo on the combined dexamethasone-corticotrophine releasing hormone test and other potential endophenotypes in healthy first-degree relatives of persons with depression', Trials, bind 10, s. 66. https://doi.org/10.1186/1745-6215-10-66

Knorr U , Vinberg M, Klose M, Feldt-Rasmussen U , Hilsted L, Gade A et al. Rationale and design of the participant, investigator, observer, and data-analyst-blinded randomized AGENDA trial on associations between gene-polymorphisms, endophenotypes for depression and antidepressive intervention: the effect of escitalopram versus placebo on the combined dexamethasone-corticotrophine releasing hormone test and other potential endophenotypes in healthy first-degree relatives of persons with depression. Trials. 2009;10:66. doi: 10.1186/1745-6215-10-66

Knorr, Ulla ; Vinberg, Maj ; Klose, Marianne et al. / Rationale and design of the participant, investigator, observer, and data-analyst-blinded randomized AGENDA trial on associations between gene-polymorphisms, endophenotypes for depression and antidepressive intervention: the effect of escitalopram versus placebo on the combined dexamethasone-corticotrophine releasing hormone test and other potential endophenotypes in healthy first-degree relatives of persons with depression. I: Trials. 2009 ; Bind 10. s. 66.

@article{a1c4c690a60111df928f000ea68e967b,

title = "Rationale and design of the participant, investigator, observer, and data-analyst-blinded randomized AGENDA trial on associations between gene-polymorphisms, endophenotypes for depression and antidepressive intervention: the effect of escitalopram versus placebo on the combined dexamethasone-corticotrophine releasing hormone test and other potential endophenotypes in healthy first-degree relatives of persons with depression",

abstract = "BACKGROUND: Endophenotypes are heritable markers, which are more prevalent in patients and their healthy relatives than in the general population. Recent studies point at disturbed regulation of the hypothalamic-pituitary-adrenocortical axis as a possible endophenotype for depression. We hypothesize that potential endophenotypes for depression may be affected by selective serotonin re-uptake inhibitor antidepressants in healthy first-degree relatives of depressed patients. The primary outcome measure is the change in plasma cortisol in the dexamethasone-corticotrophin releasing hormone test from baseline to the end of intervention. METHODS: The AGENDA trial is designed as a participant, investigator, observer, and data-analyst-blinded randomized trial. Participants are 80 healthy first-degree relatives of patients with depression. Participants are randomized to escitalopram 10 mg per day versus placebo for four weeks. Randomization is stratified by gender and age. The primary outcome measure is the change in plasma cortisol in the dexamethasone-corticotrophin releasing hormone test at entry before intervention to after four weeks of intervention. With the inclusion of 80 participants, a 60% power is obtained to detect a clinically relevant difference in the primary outcome between the intervention and the placebo group. Secondary outcome measures are changes from baseline to four weeks in scores of: 1) cognition and 2) neuroticism. Tertiary outcomes measures are changes from baseline to four weeks in scores of: 1) depression and anxiety symptoms; 2) subjective evaluations of depressive symptoms, perceived stress, quality of life, aggression, sleep, and pain; and 3) salivary cortisol at eight different timepoints during an ordinary day. Assessments are undertaken by assessors blinded to the randomization group.",

author = "Ulla Knorr and Maj Vinberg and Marianne Klose and Ulla Feldt-Rasmussen and Linda Hilsted and Anders Gade and Eva Haastrup and Olaf Paulson and J{\o}rn Wetterslev and Christian Gluud and Ulrik Gether and Lars Kessing",

note = "Keywords: Adolescent; Adult; Antidepressive Agents, Second-Generation; Citalopram; Corticotropin-Releasing Hormone; Depressive Disorder; Dexamethasone; Female; Humans; Male; Middle Aged; Phenotype; Research Design; Statistics as Topic",

year = "2009",

doi = "10.1186/1745-6215-10-66",

language = "English",

volume = "10",

pages = "66",

journal = "Trials",

issn = "1745-6215",

publisher = "BioMed Central Ltd.",

}

TY - JOUR

T1 - Rationale and design of the participant, investigator, observer, and data-analyst-blinded randomized AGENDA trial on associations between gene-polymorphisms, endophenotypes for depression and antidepressive intervention: the effect of escitalopram versus placebo on the combined dexamethasone-corticotrophine releasing hormone test and other potential endophenotypes in healthy first-degree relatives of persons with depression

AU - Knorr, Ulla

AU - Vinberg, Maj

AU - Klose, Marianne

AU - Feldt-Rasmussen, Ulla

AU - Hilsted, Linda

AU - Gade, Anders

AU - Haastrup, Eva

AU - Paulson, Olaf

AU - Wetterslev, Jørn

AU - Gluud, Christian

AU - Gether, Ulrik

AU - Kessing, Lars

N1 - Keywords: Adolescent; Adult; Antidepressive Agents, Second-Generation; Citalopram; Corticotropin-Releasing Hormone; Depressive Disorder; Dexamethasone; Female; Humans; Male; Middle Aged; Phenotype; Research Design; Statistics as Topic

PY - 2009

Y1 - 2009

N2 - BACKGROUND: Endophenotypes are heritable markers, which are more prevalent in patients and their healthy relatives than in the general population. Recent studies point at disturbed regulation of the hypothalamic-pituitary-adrenocortical axis as a possible endophenotype for depression. We hypothesize that potential endophenotypes for depression may be affected by selective serotonin re-uptake inhibitor antidepressants in healthy first-degree relatives of depressed patients. The primary outcome measure is the change in plasma cortisol in the dexamethasone-corticotrophin releasing hormone test from baseline to the end of intervention. METHODS: The AGENDA trial is designed as a participant, investigator, observer, and data-analyst-blinded randomized trial. Participants are 80 healthy first-degree relatives of patients with depression. Participants are randomized to escitalopram 10 mg per day versus placebo for four weeks. Randomization is stratified by gender and age. The primary outcome measure is the change in plasma cortisol in the dexamethasone-corticotrophin releasing hormone test at entry before intervention to after four weeks of intervention. With the inclusion of 80 participants, a 60% power is obtained to detect a clinically relevant difference in the primary outcome between the intervention and the placebo group. Secondary outcome measures are changes from baseline to four weeks in scores of: 1) cognition and 2) neuroticism. Tertiary outcomes measures are changes from baseline to four weeks in scores of: 1) depression and anxiety symptoms; 2) subjective evaluations of depressive symptoms, perceived stress, quality of life, aggression, sleep, and pain; and 3) salivary cortisol at eight different timepoints during an ordinary day. Assessments are undertaken by assessors blinded to the randomization group.

AB - BACKGROUND: Endophenotypes are heritable markers, which are more prevalent in patients and their healthy relatives than in the general population. Recent studies point at disturbed regulation of the hypothalamic-pituitary-adrenocortical axis as a possible endophenotype for depression. We hypothesize that potential endophenotypes for depression may be affected by selective serotonin re-uptake inhibitor antidepressants in healthy first-degree relatives of depressed patients. The primary outcome measure is the change in plasma cortisol in the dexamethasone-corticotrophin releasing hormone test from baseline to the end of intervention. METHODS: The AGENDA trial is designed as a participant, investigator, observer, and data-analyst-blinded randomized trial. Participants are 80 healthy first-degree relatives of patients with depression. Participants are randomized to escitalopram 10 mg per day versus placebo for four weeks. Randomization is stratified by gender and age. The primary outcome measure is the change in plasma cortisol in the dexamethasone-corticotrophin releasing hormone test at entry before intervention to after four weeks of intervention. With the inclusion of 80 participants, a 60% power is obtained to detect a clinically relevant difference in the primary outcome between the intervention and the placebo group. Secondary outcome measures are changes from baseline to four weeks in scores of: 1) cognition and 2) neuroticism. Tertiary outcomes measures are changes from baseline to four weeks in scores of: 1) depression and anxiety symptoms; 2) subjective evaluations of depressive symptoms, perceived stress, quality of life, aggression, sleep, and pain; and 3) salivary cortisol at eight different timepoints during an ordinary day. Assessments are undertaken by assessors blinded to the randomization group.

U2 - 10.1186/1745-6215-10-66

DO - 10.1186/1745-6215-10-66

M3 - Journal article

C2 - 19671139

SN - 1745-6215

VL - 10

SP - 66

JO - Trials

JF - Trials

ER -